CATX

Insider Trades

Name	Value	Action	Price	Current Price
Spoor Johan M.Director, Officer: CEO $117k100k shares BuyJun 13, 2024 $1.17 --
Woods Lori ADirector $49k4.5k shares BuyJun 14, 2024 $10.90 --
Woods Lori ADirector $89683 shares BuyJun 14, 2024 $10.80 --
Hunt Jonathan RobertChief Financial Officer $18k1.8k shares BuyJun 17, 2024 $9.82 --
Spoor Johan M.Director, Officer: CEO $21k5.4k shares BuyNov 25, 2024 $3.80 --
Spoor Johan M.Director, Officer: CEO $25k6.6k shares BuyNov 25, 2024 $3.80 --

News

proactiveinvestors.comPerspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trialproactiveinvestors.comJun 3

globenewswire.comPerspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Studyglobenewswire.comJun 3

globenewswire.comPerspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanomaglobenewswire.comMay 21

globenewswire.comPerspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studiesglobenewswire.comMay 18

Trade CATX

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

CEO: Johan Spoor
IPO Date: Nov 10, 2005

Market Data

Open: $3.02
High: $3.13
Low: $2.93
Volume: 7.7M
Avg Volume: 1.4M
52W High: $6.16
52W Low: $1.96

Valuation

Market Cap: $228M
Enterprise Value: $177M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-95M
Revenue: $884k
Net Income: $-103M
Cash: $31M
Debt: $1.6M

Events

EarningsAug 12

EPS est. -0.27